Latest in Advocacy

  • Just Announced: More Affordable Insulin Options for Medicare Beneficiaries Coming Soon

    May 26, 2020

    JDRF welcomes the May 26th announcement by the Centers for Medicare & Medicaid Services about more affordable insulin options for people in the Medicare program.

  • Insulin Affordability Matters: Advocating to Make Insulin More Affordable for All

    November 14, 2019

    More than 1.25 million Americans live with type 1 diabetes (T1D), and this number continues to grow. They need insulin several times...

  • Executive Orders on Drug Pricing

    July 28, 2020

    On July 24, the White House released three Executive Orders related to drug pricing.

  • Nation’s Largest Insurer Expands Insulin Pump Coverage

    July 1, 2020

    In a victory for JDRF’s Coverage2Control Campaign, people with T1D now have more choice in how they manage their diabetes.

  • JDRF’s One Night: The Power of Us Is Unstoppable

    June 23, 2020

    One Night. One Community. One Purpose: to show the world the undeniable power of people living with T1D.

  • Tandem Control-IQ—Now Authorized For Children

    June 17, 2020

    Tandem Diabetes announced FDA clearance of an expanded pediatric indication for the Tandem t:slim X2™ insulin pump with Control-IQ™ technology in children ages six and older.

  • JDRF Top Advances Over the Past Year

    June 9, 2020

    At JDRF, we are committed to funding the development of new therapies to keep people with type 1 diabetes (T1D) healthier, longer,...

  • Enhanced Charitable Giving Incentives Explained: What it Means for Donors in 2020

    April 23, 2020

    What the federal economic relief package, also known as the CARES Act (Coronavirus Aid, Relief, and Economic Security) means for donors to JDRF.

  • New JDRF-Funded Study finds Lifetime T1D Management Costs a Collective $813 Billion

    February 24, 2020

    Cost for each diagnosed American is nearly $500,000.